Axxcess Wealth Management LLC reduced its stake in shares of VanEck Pharmaceutical ETF (NASDAQ:PPH – Free Report) by 12.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,239 shares of the company’s stock after selling 1,394 shares during the period. Axxcess Wealth Management LLC owned 0.17% of VanEck Pharmaceutical ETF worth $929,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Steward Partners Investment Advisory LLC increased its position in VanEck Pharmaceutical ETF by 2.6% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 7,296 shares of the company’s stock worth $594,000 after purchasing an additional 185 shares in the last quarter. Aspiriant LLC lifted its stake in VanEck Pharmaceutical ETF by 5.6% during the first quarter. Aspiriant LLC now owns 6,000 shares of the company’s stock worth $544,000 after purchasing an additional 320 shares during the last quarter. Allworth Financial LP bought a new position in VanEck Pharmaceutical ETF during the fourth quarter worth $28,000. Global Retirement Partners LLC lifted its stake in VanEck Pharmaceutical ETF by 2,343.8% during the first quarter. Global Retirement Partners LLC now owns 391 shares of the company’s stock worth $35,000 after purchasing an additional 375 shares during the last quarter. Finally, Edge Financial Advisors LLC bought a new position in VanEck Pharmaceutical ETF during the first quarter worth $248,000.
VanEck Pharmaceutical ETF Trading Up 0.7 %
PPH traded up $0.65 on Friday, reaching $93.28. The company had a trading volume of 256,744 shares, compared to its average volume of 135,693. The company has a fifty day moving average of $91.57 and a 200-day moving average of $89.08. The company has a market capitalization of $619.38 million, a P/E ratio of 21.04 and a beta of 0.72. VanEck Pharmaceutical ETF has a one year low of $74.05 and a one year high of $93.85.
VanEck Pharmaceutical ETF Cuts Dividend
VanEck Pharmaceutical ETF Profile
The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.
Featured Articles
- Five stocks we like better than VanEck Pharmaceutical ETF
- What Are Dividend Achievers? An Introduction
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- Best Stocks Under $5.00
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- The Significance of Brokerage Rankings in Stock Selection
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Want to see what other hedge funds are holding PPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for VanEck Pharmaceutical ETF (NASDAQ:PPH – Free Report).
Receive News & Ratings for VanEck Pharmaceutical ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Pharmaceutical ETF and related companies with MarketBeat.com's FREE daily email newsletter.